



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/629,611	07/30/2003	Koji Nozaki	030922	6117		
38834	334 7590 05/03/2006		EXAMINER			
WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP 1250 CONNECTICUT AVENUE, NW			SANDERS, KRIELL	SANDERS, KRIELLION ANTIONETTE		
SUITE 700	CIICUI AVENUE, NW	ART UNIT	PAPER NUMBER			
WASHINGTO	WASHINGTON, DC 20036			1714		
			DATE MAILED: 05/03/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application No. Applicant(s		Applicant(s)				
		10/629,611		NOZAKI ET AL.				
		Examiner	-	Art Unit				
		Kriellion A. Sand	ders	1714				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SH WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS CO 36(a). In no event, how will apply and will expire cause the application	OMMUNICATION vever, may a reply be time s SIX (6) MONTHS from the to become ABANDONED	. ely filed the mailing date of this communication. 0 (35 U.S.C. § 133)				
Status								
2a)☐	Responsive to communication(s) filed on 2/27/8 This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-fir	rmal matters, pros					
Dispositi	ion of Claims							
5) ☐ 6) ☑ 7) ☐ 8) ☐ Applicati 9) ☐ 10) ☐	Claim(s) 1-20 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1-20 is/are rejected. Claim(s) is/are objected to. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or are subject to restriction and/or are subject to by the Examine The specification is objected to by the Examine The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Graph Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correction of the oath of the oath of the oath or dec	wn from consider r election require r. epted or b) ob drawing(s) be held ion is required if the	ement. jected to by the E I in abeyance. See ne drawing(s) is obje	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority u	ınder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) 🔲 Notic 3) 🔀 Inforn	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	5) 🔲	Interview Summary (I Paper No(s)/Mail Dat Notice of Informal Pa Other:					

DETAILED ACTION

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 1097967A2 in view of Haskitani et al, US Patent No. 5545485, Frechtling et al, US Patent No. 3971753 and Olison et al, US Patent No. 6890546.
- 3. The European Patent discloses biodegradable resin compositions comprising a biodegradable polyester resin, such as polylactic acid and other known adjuvants including fillers, anionic surfactants, fibrous materials, flame retardants and nucleating agents. The fillers are employed in an amount of 5 to 90% by weight of the composition. Patentee indicates one suitable filler material to be talc. Suitable nucleating agents include mica, talc, silica, phosphates and phosphates. These are all components set forth in applicant's claims and their properties are inherent to the components. The compositions of the invention may be formed into molded products. Patentee does not suggest the encapsulation of the filler in biodegradable resin, however he does suggest encapsulation of the filler with a surfactant to improve the dispersibility of the filler in the biodegradable resin. See page 4, lines 5-9, page 5, lines 37-48 and page 8, line 36 through page 9, line 57.

Hashitani et al discloses a biodegradable resin molded article derived from a material obtained by kneading, melting or mixing a biodegradable resin and a biodegradable additive. Art Unit: 1714

Examples of such a <u>biodegradable resin</u> raw material include a polyester which is produced by microorganisms, an aliphatic polyester, polyvinyl alcohol, polycaprolactone, polyhydroxyalkanoate, denatured starch, a natural polymer and a polyisocyanate.

The <u>additive</u> may function as a plasticizer, a filler or a flame retardant depending on the kind of the material desired. Additionally, a biopolymer having biodegradability may be used as one of the <u>additives</u>. Such a biopolymer includes vegetable oil, collagen or a high- or super-high thermophilic bacteria, that may be decomposed by bacteria. See col. 2, lines 13-19 and col. 3, line 25 through col. 4, line 17.

Frechtling et al discloses the process of coating filler material with polymeric substrates. See col. 2, lines 48-69.

Mollison et al discloses a medical device comprising a supporting structure having a coating on the surface thereof, the coating containing a therapeutic substance, such as, for example, a drug. The suggested diameter of the substance to be coated is 0.1 to 10 micrometers. See col. 17, lines 5-20. The purpose of the coating is to serve as a controlled release vehicle for the therapeutic agent.

The coating can be polymeric and can further be hydrophilic, hydrophobic, biodegradable, or non-biodegradable. The material for the polymeric coating can be selected from the group consisting of polycarboxylic acids, cellulosic polymers, gelatin, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, polyurethanes, silicones, polyorthoesters, polyanhydrides, polycarbonates, polypropylenes, polylactic acids, polyglycolic

Art Unit: 1714

acids, polycaprolactones, <u>polyhydroxybutyrate</u> valerates, polyacrylamides, polyethers, and mixtures and copolymers of the foregoing. See col. 4, lines 57-67 and col. 12, lines 24-45.

Mollison is looked to specifically to document that coating materials based upon polycaprolactones, polyhydroxybutyrate valerates exhibit controlled release or biodegradable activity and would be an acceptable coating material for a filler requiring controlled release capabilities.

It would have been obvious to one of ordinary skill in the art at the time of applicant's invention to utilize coated filler materials such as taught by Frechtling et al, as a biodegradable filler material as taught by Hashitoni et al to fulfill the filler material suggested by the European patent. Furthermore, it would have been obvious to utilize a time-released or biodegradable coating for that filler material such as taught by Mollison et al if biodegradable properties for the filer material were desired. The prior art does not indicate that the biodegradable resin used to encapsulate the filler should be different that the biodegradable resin substrate of the composition. Therefor it is obvious to use the same biodegradable resin for both applications to achieve a homogenous composition.

Information Disclosure Statement

Applicant is advised that the document from the Taiwan office cited on the 1449 filed 2/27/06 was not received and has not been considered.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kriellion A. Sanders whose telephone number is 571-272-1122. The examiner can normally be reached on Monday through Thursday 6:30-7:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vasu Jagannathan can be reached on 571-272-1119. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kriellion A. Sanders Primary Examiner Art Unit 1714